The Board has indicated that the results of the clinical trial indicate that VG-0001 performed no better than standard care. If the trial involved the use of standard care plus VG-0001 (and plus placebo), on what basis does the Board deduce that VG-001 performed no better than standard care?
To what extent, if any, is the new cancer treatment "derisked" with "proven safety and effectiveness"?
FTT Price at posting:
0.4¢ Sentiment: None Disclosure: Held